Endocrine changes and clinical profiles in depression: I. The dexamethasone suppression test

S. P. CALLOWAY, R. J. DOLAN, P. FONAGY, V. F. A. DE SOUZA AND A. WAKELING

From the Academic Department of Psychiatry, Royal Free Hospital, London

SYNOPSIS Hypothalamic-pituitary-adrenal axis function was investigated in 72 patients with primary depression. Forty-four per cent of the patients demonstrated abnormal suppression of their cortisol levels after a 1 mg overnight dexamethasone suppression test. Patients with abnormal suppression ('non-suppressors') were not clearly distinguished from 'suppressors' by the commonly used diagnostic classifications. They did not appear to be more severely depressed, but they were more likely than the 'suppressors' to be in-patients. Multivariate analysis of the data suggested that two clinical features were independently associated with non-suppression: the PSE syndromes of Slowness and General Anxiety. However, the association of these syndromes with non-suppression was relatively weak, indicating that the clinical significance of the dexamethasone suppression test is, as yet, unclear. The results raise doubts about the validity of using the dexamethasone suppression test as a diagnostic marker for a specific depressive syndrome.

INTRODUCTION

There has been considerable interest in the neuroendocrine changes associated with depression. Most of the research in this area has focused primarily on the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axes. Recent interest has been stimulated by reports of abnormalities of the dexamethasone suppression test (DST) and thyrotropin-releasing hormone test (TRH-test) in patients with depression and the possibilities of using these tests as diagnostic aids. The present paper reports on the DST in a group of 72 depressed patients with clearly defined clinical characteristics. A subsequent paper will consider the results of the TRH-test in the same group.

Early investigation of the hypothalamic-pituitary-adrenal (HPA) axis revealed that plasma and urinary cortisol levels, and cortisol production rate, tended to be high in depressed patients, with levels returning to normal on clinical recovery (Board et al. 1957; Gibbons & McHugh, 1962; Sachar et al. 1973; Carroll, 1976). More recent work has focused on dynamic tests to assess HPA function. Dexamethasone, a synthetic corticosteroid, inhibits ACTH and cortisol production by the negative feedback mechanism. There is normally suppression of endogenous cortisol production for 24-28 hours after a 1 mg dose at night (Krieger et al. 1971). Several investigators have shown that some patients with depression fail to suppress cortisol levels after dexamethasone (Butler & Besser, 1968; Carroll et al. 1968; Stokes et al. 1976). Carroll et al. (1976) demonstrated that there was early escape from suppression rather than absolute non-suppression. Subsequent studies with psychiatric and normal controls reported that this finding was relatively specific to patients with depression and that, in addition, the test reverted to normal on clinical recovery (Carroll et al. 1981). The proportion of depressed patients who are 'non-suppressors' has been found to vary between 24% (Holsboer et al. 1980; Amsterdam et al. 1982) and 69% (Nuller & Ostroumova, 1980).

Carroll (1982), reporting on the use of the DST in over 400 subjects, found that about 50% of patients with an 'endogenous' depressive profile showed non-suppression. However, attempts to
use the DST as a diagnostic marker for endogenous depression have produced conflicting results. Some studies have found that the test was effective in distinguishing endogenous from non-endogenous depression (Carroll et al., 1981; Holden, 1983); however, this finding was not confirmed in other studies (Holsboer et al., 1980; Davis et al., 1981; Targum et al., 1982; Berger et al., 1982).

Inconsistency across the studies relating to the clinical features associated with non-suppression may be related to a number of factors: lack of strict diagnostic criteria, poor definition of patient groups, possible effects of drugs (Butler et al., 1968; Platman & Fieve, 1968; Langer et al., 1979; Beary et al., 1983), physical illness in the patient groups (Murray, 1967; Brown et al., 1979), and failure to account for the relationship between non-suppression and certain clinical variables such as anxiety. Early investigators reported that anxiety symptoms were particularly associated with cortisol hypersecretion (Gibbons et al., 1960; Sachar et al., 1970; Stokes et al., 1976). This relationship may have been obscured in some recent studies by the inclusion of patients who were on drugs (e.g. Brown & Shuey, 1980; Aggermaes et al., 1983). Psychotropic drugs not only affect endocrine function but also mental state, thus obscuring possible relationships between endocrine status and symptom profiles. Admission to hospital, environmental and psychological stresses have also been shown to affect the HPA axis (Sachar, 1967; Mason, 1968).

The aim of this study was to investigate the significance of the DST in drug-free patients with primary depression who had been carefully screened for physical illness and to determine the clinical features associated with non-suppression.

**METHOD**

**Patients**

The patients were admitted to the study from several sources: a psychiatric hospital, a district general/teaching hospital (in-patients, out-patients, Accident/Emergency), a psychiatric day hospital, and directly from general practice. One hundred and thirty patients were interviewed over a 2-year period; those with physical illnesses, secondary depression, or in whom it was considered unethical to interrupt or delay treatment were excluded from the study. Patients over the age of 70 were also excluded from the study, as were all those who met any of Carroll's exclusion criteria which invalidate the DST (Carroll, 1980). The remaining 80 patients all met the Research Diagnostic Criteria (RDC) for depression (Spitzer et al., 1978) and were drug-free for a minimum period of one week before endocrine investigations were carried out. In some patients placebo medication was given at night, and 13 patients (16.2%) received 10–20 mg of temazepam at night. These 13 patients showed a very slight, non-significant trend towards higher cortisol output than the rest of the group; there were no other differences and the patients were included in the investigations.

Of the 80 patients investigated, 8 were excluded from the analysis. Five of these 8 received alternative psychiatric diagnoses on follow-up (one schizophrenia, two schizoaffective, one anorexia nervosa and one Pick's disease). Of the remaining 3 patients, one was found to have a brain tumour following CT scan, one developed pneumonia, and one failed to complete the investigations. Only patients with primary depression were included in the sample. These 72 patients were classified by means of the RDC as Major Depressive Disorder (54), Probable Major Depressive Disorder (9) and Minor Depressive Disorder (9).

**Table 1. Clinical features of patient group**

(N = 72)

<table>
<thead>
<tr>
<th>Demographic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (mean ± s.d.)</td>
<td>41 ± 13.7</td>
</tr>
<tr>
<td>Sex: female</td>
<td>43 (59.7)</td>
</tr>
<tr>
<td>In-patient</td>
<td>28 (38.9)</td>
</tr>
<tr>
<td>Previous history</td>
<td>3.7 ± 2.8</td>
</tr>
<tr>
<td>Previous episodes (mean ± s.d.)</td>
<td>20 (27.8)</td>
</tr>
<tr>
<td>Presenting with first episode</td>
<td>32 ± 15.4</td>
</tr>
<tr>
<td>Age of onset of first episode (mean ± s.d.)</td>
<td>20 ± 7.1</td>
</tr>
<tr>
<td>Previous treatment</td>
<td>32 (44.4)</td>
</tr>
<tr>
<td>Triyclic antidepressants</td>
<td>8 (11.1)</td>
</tr>
<tr>
<td>MAOIs</td>
<td>27 (37.5)</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>6 (8.3)</td>
</tr>
<tr>
<td>ECT</td>
<td>20 ± 7.1</td>
</tr>
<tr>
<td>Hamilton score (mean ± s.d.)</td>
<td>6 (8.3)</td>
</tr>
<tr>
<td>CATEGO classes</td>
<td>33 (46.9)</td>
</tr>
<tr>
<td>Depressive psychosis</td>
<td>29 (40.3)</td>
</tr>
<tr>
<td>Anxiety neurosis</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td>Paranoia</td>
<td>5 (6.9)</td>
</tr>
<tr>
<td>Obsessional neurosis</td>
<td>1 (1.4)</td>
</tr>
</tbody>
</table>

The table shows the number of patients, with the percentages in parentheses.
unipolar and 8 bipolar cases. On the basis of the
Newcastle Diagnostic Index 36 patients (50%) were
classified as 'endogenous' and 36 (50%) as
neurotic. Thirty-five of the patients (48-6%) were
classified as 'endogenous', using the Discriminant
Index of Feinstein & Carroll (1982). Clinical and
demographic features are shown in Table 1. Using
the PSE Index of Definition (ID) (Wing
et al., 1978), 70 of the 72 patients met the criteria
of 'caseness' (an ID of 5 or more) and the
remaining 2 patients had an ID of 4. The
distribution by CATEGO classes is also shown in
Table 1.

Clinical assessment
After the initial interview and physical examination,
aedematological and routine biochemical
investigations were performed, and all but 7 of
the patients had an EEG. Clinical data included
the Hamilton Rating Scale (Hamilton,
1967), the Newcastle Diagnostic Index (Carney
et al., 1965), the Discriminant Index of Feinstein
& Carroll (1982), and the Present State Examination
(PSE) (Wing et al., 1974). Close attention
was paid to the course of illness, past history and
family history. Family history data were collected
from a family member where possible (64 cases).
Data on the social variables were collected using
the Bedford College Life Events and Difficulties
Schedule (Brown & Harris, 1978).

Procedures
A three-day 'acclimatization' period was allowed
for in-patients before endocrine tests were
performed, during which time the clinical
interviews took place. In patients with extreme
retardation the full interview was delayed until
some clinical improvement had taken place. On
Day 1 a 24-hour urine collection was taken from
11 p.m. to 11 p.m. the next day (Day 2), when
1 mg of dexamethasone was given orally at
11 p.m., and a second 24-hour urine collection
started. Blood was taken for plasma cortisol at
4 p.m. on Day 3. The first 24-hour urine was used
to give the baseline cortisol production. The
second 24-hour urine provided information on
post-dexamethasone urinary free cortisol output
which has been shown to be a good discriminator
of depressed from non-depressed patients (Carroll
& Curtis, 1976). A TRH-test was performed on
Day 4 or Day 5, and is described in the
subsequent paper (Calloway et al. 1984). Out-
patients made both 24-hour urine collections at
home and came to the ward for the plasma
sample, but 10 out-patients were admitted for
short periods specifically for the study.

Assays
Cortisols in plasma and urine were measured in
duplicate using a double antibody radio-
immunoassay method (Amerlex Cortisol RIA
kit). The coefficient of variation for repeated
assays was 4.4%. The normal range for 24-hour
urinary free cortisols using this method is
35-120 μg/24 hours, although the upper range
for this laboratory is as taken as 130 μg/24 hours.

Analysis of results
The patients were grouped according to the
results of the DST or the TRH-test, and the mean
levels of a number of endocrine variables were
compared in these groups using one-way
analysis of variance. Many of these variables
appeared to have log-normal distributions;
consequently, log transformations were
performed before parametric statistical analyses
were carried out. The associations between
endocrine variables were examined using Pearson
product-moment correlations. The associations
between patients grouped according to the
results of the DST or TRH-test and the common
diagnostic classifications were examined using
chi-squared tests or Jonckheere's trend test
(Leach, 1979), the latter being used in cases
where the diagnostic groupings could be ranked.
The significance of the normalized, corrected
Kendall's S statistic (S) is reported. The clinical
features and scores on psychiatric rating scales
of patients grouped according to the DST or
TRH-test were compared, using one-way
analysis of variance for continuous variables and
chi-squared tests for categorical variables. The large
count of univariate statistical tests performed
increased the likelihood of the analysis yielding
false positive errors and this mandates caution in
the interpretation of these results. In order to
reduce the likelihood of obtaining significant
effects by chance, two precautionary measures
were taken whenever multiple univariate statistics
were performed: first, variables which signifi-
cantly correlated with one or more of the other
variables were eliminated from the analysis;
secondly, the level for rejecting the null
hypothesis was increased to the 1% level of
significance. A step-wise discriminant function analysis (Jennrich, 1977) was carried out in an attempt to identify the clinical features which in combination could best identify patients with abnormalities on the DST or TRH-test.

RESULTS

(a) Urinary-free cortisols (UFC) and DST

Plasma cortisols were estimated on all 72 patients, pre-dexamethasone UFCs on 65 patients and post-dexamethasone UFCs on 70 patients. The mean pre-dexamethasone 24-hour UFC was 158.6 µg/24 hours (s.d. = 77.8, range 33–378). Thirty-eight of the patients (58.5%) had a 24-hour secretion above the normal range (25–130 µg/24 hours). The mean post-dexamethasone 24-hour UFC was 65.4 µg/24 hours (s.d. = 56.3, range 6–232). The mean 4 p.m. plasma cortisol was 6.2 µg/dl (s.d. = 7.0, range 0.5–35). Using the 5 µg/dl cut-off point for non-suppression (Carroll, 1982), 28 patients were classified as ‘non-suppressors’.

There were significant correlations between pre- and post-dexamethasone UFC levels (r = 0.708, df = 62, P < 0.001) and between post-dexamethasone plasma cortisol and post-dexamethasone UFC levels (r = 0.789, df = 67, P < 0.001). Using a linear regression function, the post-dexamethasone UFC value corresponding to a plasma level of 5 µg/dl was found to be 58.01 µg/24 hours. The value of 58 µg/24 hours was taken as a UFC cut-off point for non-suppression. This resulted in 27 patients (38.6%) being classified as ‘non-suppressors’. The two methods of identifying ‘non-suppressors’ overlapped closely. Five patients identified as ‘non-suppressors’ by plasma levels fell into the ‘suppressor’ category as defined by UFC levels. Conversely, 4 patients identified as ‘non-suppressors’ by UFC levels fell into the ‘suppressor’ category as defined by a plasma level of 5 µg/dl. When results from both methods were taken together, 32 patients (44.4%) were classified as ‘non-suppressors’, and this group was used in the subsequent analysis. All but 2 of these patients met the more stringent criteria of having a 4 p.m. plasma cortisol above 6 µg/dl and/or a post-dexamethasone UFC above 75 µg/24 hours. When the subsequent analyses were duplicated, using just the plasma cortisol values to define non-suppression, the results were essentially the same as when the above criteria were used.

(b) Relationship between non-suppression and diagnostic categories of depression

The frequency of ‘non-suppressors’ in groups defined by current methods of classifying or subdividing depression is shown in Table 2. There was a trend for ‘non-suppressors’ to appear with above chance frequency among patients classified as definite Major Depressive Disorder on the RDC, and also among those classified as having definite or probable endogenous subtype of Major Depressive Disorder within this classification system. The proportion of ‘non-suppressors’ was similar in patients classified as endogenous and in those classified as neurotic by the Newcastle Diagnostic Index. Nevertheless, there was a trend for the endogenous category, as defined by Feinberg & Carroll’s Discriminant Index, to contain more ‘non-suppressors’ than ‘suppressors’. The proportion of ‘non-suppressors’ was similar in the patient groups derived from the Iowa Classification (Winokur, 1979). When patients were grouped by PSE classes, 5 out of 6 patients classified under Psychotic Depression were ‘non-suppressors’; 60.6% of patients in the Retarded Depression class were ‘non-suppressors’, compared with 24.1% of those in the Neurotic Depression class (X² = 8.35, P < 0.01).

(c) Clinical features associated with the DST

The clinical features of ‘non-suppressors’ and ‘suppressors’ are shown in Table 3. Features not present in the table – such as weight, height and weight/height ratio – did not differ between the groups. There was no significant age difference between the two groups, although the ‘non-suppressors’ tended to be older.

The presence or absence of long-term difficulties or major life events in the 6 months prior to onset did not differentiate the two groups. There was a significantly greater proportion of ‘non-suppressors’ among in-patients in comparison with out-patients. This may have been due to hospitalization itself or to patient characteristics associated with a recommendation for admission.

To examine this question, a sample of 10 patients who would normally have been seen and treated as out-patients were admitted for the duration of the tests, allowing the same ‘acclimatization’
Dexamethasone suppression test in depression

Table 2. Number and percentage of ‘non-suppressors’ in various diagnostic sub-divisions of depression

<table>
<thead>
<tr>
<th>Research Diagnostic Criteria</th>
<th>Total no. of patients</th>
<th>‘Non-suppressors’</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Major depressive disorder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i) Definite</td>
<td>54</td>
<td>28 (51.8)</td>
<td></td>
</tr>
<tr>
<td>(ii) Probable</td>
<td>9</td>
<td>2 (22.2)</td>
<td></td>
</tr>
<tr>
<td>B. Minor depressive disorder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Endogenous depressive disorder (i) Definite</td>
<td>34</td>
<td>19 (55.9)</td>
<td></td>
</tr>
<tr>
<td>(ii) Probable</td>
<td>15</td>
<td>7 (46.7)</td>
<td></td>
</tr>
<tr>
<td>B. Non-endogenous depressive disorder</td>
<td>23</td>
<td>6 (26.1)</td>
<td></td>
</tr>
<tr>
<td>Newcastle Diagnostic Index</td>
<td>A. Endogenous</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>B. Neuropathic symptoms</td>
<td>36</td>
<td>17 (47.2)</td>
<td></td>
</tr>
<tr>
<td>Discriminant Index (Feinberg &amp; Carroll, 1982)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Endogenous</td>
<td>35</td>
<td>20 (57.1)</td>
<td></td>
</tr>
<tr>
<td>B. Uncertain</td>
<td>18</td>
<td>7 (38.9)</td>
<td></td>
</tr>
<tr>
<td>C. Non-endogenous</td>
<td>19</td>
<td>5 (26.3)</td>
<td></td>
</tr>
<tr>
<td>PSE classes</td>
<td>A. Depressive psychosis</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>B. Retarded depression</td>
<td>33</td>
<td>20 (60.6)</td>
<td></td>
</tr>
<tr>
<td>C. Neuropathic depression</td>
<td>29</td>
<td>7 (24.1)</td>
<td>P &lt; 0.01</td>
</tr>
<tr>
<td>Iowa Classification</td>
<td>A. Bipolar (I–II)</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>B. Unipolar</td>
<td>64</td>
<td>29 (45.3)</td>
<td></td>
</tr>
<tr>
<td>(i) Pure familial depressive disease</td>
<td>18</td>
<td>10 (55.5)</td>
<td></td>
</tr>
<tr>
<td>(ii) Sporadic depressive disease</td>
<td>25</td>
<td>8 (32.0)</td>
<td></td>
</tr>
<tr>
<td>(iii) Depressive spectrum disease</td>
<td>21</td>
<td>11 (52.4)</td>
<td></td>
</tr>
</tbody>
</table>

* Results of Jonckheere's test.
† Results of chi-squared test.

Table 3. Clinical features of ‘non-suppressors’ (N = 32) and ‘suppressors’ (N = 40)

<table>
<thead>
<tr>
<th></th>
<th>‘Non-suppressors’</th>
<th>‘Suppressors’</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean ± s.d.)</td>
<td>44.3 ± 14.1</td>
<td>39.6 ± 13.4</td>
<td>NS</td>
</tr>
<tr>
<td>Family history of depression (%)</td>
<td>53.1</td>
<td>32.5</td>
<td>NS</td>
</tr>
<tr>
<td>Previous history (mean ± s.d.)</td>
<td>33.5 ± 16.5</td>
<td>32.4 ± 14.6</td>
<td>NS</td>
</tr>
<tr>
<td>Age at onset of first episode (yr)</td>
<td>1.2 ± 1.7</td>
<td>0.5 ± 0.9</td>
<td>F = 4.31; df = 1, 70; P &lt; 0.05</td>
</tr>
<tr>
<td>Number of previous admissions</td>
<td>7 ± 4.5</td>
<td>6 ± 3</td>
<td></td>
</tr>
<tr>
<td>Current episode</td>
<td>8 ± 4.5 ± 1.7</td>
<td>7.4 ± 7.4</td>
<td>NS</td>
</tr>
<tr>
<td>Duration (months)</td>
<td>59.6 ± 14.6</td>
<td>22.5 ± 9.4</td>
<td></td>
</tr>
<tr>
<td>In-patients (%)</td>
<td>56.3</td>
<td>52.3</td>
<td>NS</td>
</tr>
</tbody>
</table>

period as for the other in-patients. There was no difference between the cortisol output of this group when compared with the out-patient group, suggesting that the high proportion of ‘non-suppressors’ in the in-patient group is due to their clinical status, rather than to admission per se.

Previous treatment, in the distant or recent past, was not associated with non-suppression. Of the 13 patients currently taking a medication, 11 were clear-cut ‘non-suppressors’ (N = 7) or ‘suppressors’ (N = 4), I was a borderline ‘non-suppressor’, and I a borderline ‘suppressor’. The mean scores of ‘non-suppressors’ and ‘suppressors’ on a number of rating scales and PSE syndromes are shown in Table 4. The Discriminant Index score was significantly higher for ‘non-suppressors’. The PSE syndrome score which significantly differentiated between ‘non-suppressors’ and ‘suppressors’ was SL (Slowness), the PSE measure of retardation,
consisting of the symptoms of slowness and restriction of movement and speech. The difference in scores for GA (General Anxiety), which combines free-floating anxiety, panic attacks and observed anxiety, approached significance. The scores on other PSE syndromes, including ED (special features of depression), consisting of guilt, loss of affect, dulled perception, did not differ between the groups.

In order to determine which of the above features were most important in identifying a patient as either a ‘non-suppressor’ or a ‘suppressor’, a stepwise discriminant function analysis was performed. In addition to the PSE syndrome scores, the total PSE score, Hamilton rating, Newcastle rating, and age were included in this analysis. Only two variables – the PSE syndromes of general anxiety and slowness – were selected by the procedure to be entered into the discriminant function. A jack-knifed classification was performed.1 Slowness was entered first and correctly classified 63.9% of the patients. The entry of General Anxiety into the discriminant function improved the number of patients correctly classified by four. The function based on values of Slowness and General Anxiety was able to classify 70.8% of patients (64.3% of ‘non-suppressors’ and 75.0% of ‘suppressors’).

There was no correlation between General Anxiety and Slowness (r = -0.03), and they appeared to be relatively independent features defining non-suppression. This could suggest that there were two sub-groups within the ‘non-suppressor’ group. They were therefore arbitrarily divided into those who were predominantly retarded (Slowness of 2 or more, or Slowness of 1 with GA of 0 or 1) and those manifesting predominantly anxious symptomatology (GA of 2 or more and Slowness less than 2, or GA of 1 with Slowness of 0). These two groups were compared on a variety of clinical variables. The results of this analysis did not show any major differences between the two groups. There was no relationship between the two subgroups and the PSE classes (D, R or N).

Life events in the 6 months prior to onset were equally prevalent in both groups. Agitation was present in both groups. The retarded ‘non-suppressors’, however, had an older age at onset than the anxious ‘non-suppressors’ (42.2 ± 18.4, compared with 27.6 ± 12.4); this difference was significant, using the Brown & Forsythe (1974) statistic for unequal variances (F = 6.26; df = 1, 30; P < 0.05).

**DISCUSSION**

This group of 72 patients who were drawn from a wide variety of sources, including general practice, showed a considerable degree of HPA axis disinhibition. Forty-four per cent of patients had abnormal suppression of cortisol after 1 mg of dexamethasone, a figure comparable with that found in previous studies (Carroll, 1982).

The commonly used classificatory systems for depression did not identify accurately the patients with non-suppression. We found that about 50% of patients with ‘endogenous’ features of depression tended to be ‘non-suppressors’. The retarded group on the PSE classification contained a similar proportion. However, 24% of patients classed as neurotic depression by the PSE and 41% of patients classified as neurotic by the Newcastle Scale were also found to be ‘non-suppressors’. Similar

---

1 The jack-knifed classification was performed by eliminating each case in turn to be classified from the computations of group means and cross-products (Lachenbruch & Mickey, 1968).
findings have been reported by Holsboer et al. (1980), Berger et al. (1982) and Peselow et al. (1983), although Holden (1983) reported that patients with endogenous depression as defined by the Newcastle Scale were more likely to be 'non-suppressors' than those defined as neurotic.

There are several possible explanations for the discrepancies found in different studies. These include the assay techniques used, the nature of the patient population under investigation, the effects of medication and the means used to classify patients as 'endogenous' or 'neurotic', especially with regard to the presence or absence of precipitants.

Radio-immunoassay (RIA) techniques have been widely used for assaying plasma and urinary corticosteroids in endocrine studies in depression, but a competitive protein binding (CPB) method has been used in some studies, including that of Carroll et al. (1981). Wood et al. (1983) reported that different RIA kits gave different mean cortisol levels when a series of samples were assayed, although the results did correlate with each other. Meltzer & Fang (1983) reported that, in general, RIA methods for assaying cortisols gave results which were about 25% greater than those obtained by CPB methods. Thus, patients identified as 'non-suppressors' by RIA cortisol measurement would not necessarily be classified as 'non-suppressors' by the CPB method. However, Meltzer & Fang found a close correlation between the results obtained from the CPB method and those from the Amerlex RIA kit ($r = 0.95$), which is the kit used in the present study. The RIA method tended to give higher cortisol levels than the CPB method, with a mean difference of $0.79 \pm 1.22$ µg/dl. However, the differences were more likely to occur with higher cortisol concentrations. These authors reported that only one sample which was assayed as being greater than 5 µg/dl on the CPB method was found to be less than 5 µg/dl on the Amerlex RIA kit.

Another recent study also found a close correlation between the results of the CPB and RIA methods for assaying cortisols (Wilens et al. 1983). In contrast to the findings of Meltzer & Fang (1983), Wilens et al. reported that the RIA method gave results which were about 7% lower than those from the CPB method.

In the present study all but two of the patients who were 'non-suppressors' when the 5 µg/dl cut-off point was used had cortisol levels which fell above the 6 µg/dl cut-off point, and many had distinctly higher values. Moreover, the post-dexamethasone UFC levels provided confirmation for the plasma cortisol values. It is likely that nearly all the patients in this study would also have been classified as 'non-suppressors' had the CPB method been used, thus allowing valid comparisons to be made with the results of Carroll et al. (1981) and other studies.

Patient selection may also influence the results. In the present study it emerged that 5 out of 6 patients with psychotic symptomatology (delusions and/or hallucinations) were 'non-suppressors', a similar proportion to that reported by Mendlewicz et al. (1982). The presence of a large number of psychotic patients in a population under investigation could result in a greater association between 'endogenous' depression and non-suppression than would occur in studies such as those of Amsterdam et al. (1982) which was performed on an out-patient population.

The effects of medication on patients' endocrine status and symptomatology must also be taken into account in view of the fact that many studies include patients on tricyclic antidepressants and/or tranquilizers. Depressed patients treated with psychotropic drugs may experience relief from anxiety before other symptoms of depression are alleviated. Such patients would then be more likely to be classified as having endogenous depression on the Newcastle Scale (because of the negative loading for anxiety) than if they had remained drug-free. Because some of these patients would be 'non-suppressors' (as shown in the present study), this could produce a bias towards an association between 'non-suppressor' status and endogenous depression. It is possible that the present study would have demonstrated a stronger association between anxiety and non-suppression if the 13 patients taking temazepam had received placebos instead.

A further possible source of bias arises from the method used to determine the presence or absence of precipitating life events which, in turn, influences whether someone is classified as endogenous or neurotic. The present study is the first in the field to have used the Bedford College...
Life Events and Difficulties Schedule (LEDS) to collect these data. This instrument provides a contextual rating of the severity of life events, and thus an objective assessment as to whether a significant precipitating life event is present or absent (irrespective of what the patient thinks to be significant). When a subjective assessment of the presence or absence of precipitants is used — as with the Newcastle Scale or Feinberg & Carroll’s Discriminant Index — it is possible that retarded or guilty patients would under-report precipitating events, being less likely to blame external circumstances for their plight. This could lead to an artificial association between endogenous symptomatology (retardation, guilt, etc.) and the absence of precipitants. Both the Newcastle Scale and the Discriminatory Index of Feinberg & Carroll (1982) load negatively for ‘endogenous’ depression if a precipitating event is judged to be present. In this study, however, we found that patients with ‘endogenous’ features of depression were just as likely to have significant preceding life events as those with ‘non-endogenous’ features, a finding reported by previous authors (Goodwin & Bunney, 1972; Hirschfeld, 1981). ‘Non-suppressors’ were as likely as ‘suppressors’ to have experienced significant life events in the 6 months prior to onset. The Discriminant Index of Feinberg & Carroll and the Newcastle Scale would have distinguished more effectively between ‘non-suppressors’ and ‘suppressors’ in this population if the negative loading for ‘precipitants’ had been excluded.

These results, taken in conjunction with those of previous studies, suggest that non-suppression is not restricted to any particular depressive syndrome. This suggests that the phenomenon may also occur to specific processes occurring in depressed patients, more commonly in those patients with ‘endogenous’ symptomatology. Such processes may also occur in other conditions, as non-suppression has been reported in some patients with schizophrenia (Shulman & Diebold, 1977), anorexia nervosa (Gerner & Gwirtsman, 1981), bulimia nervosa (Hudson et al., 1982), dementia (Spar & Gerner, 1982) and chronic ‘psychogenic’ pain (Blumer et al., 1982). Suwa et al. (1974), in a large study of HPA function in a heterogeneous population of psychiatric patients, suggested that there could be two factors accounting for disinhibition of the HPA axis: ‘emotional turmoil’ and ‘disease processes involving certain areas of the central nervous system’ (such as the temporal lobes).

In the present study there was no association between non-suppression and the severity of the depressed mood itself. Longitudinal studies on depressed patients have also found that changes in cortisol levels are not related to change in depressed mood as a symptom but to other features, such as anxiety (Gibbons et al., 1980; Sachar, 1967). Our findings suggest that two of the determinants of ‘non-suppressor’ status were retardation and anxiety. An association between ‘non-suppressor’ status and anxiety has also been reported by Stokes et al. (1976) and by Reus (1982). In addition, an association between non-suppression and retardation has been reported by Brown & Shuey (1980) and by Agron & Wide (1982).

As retardation and anxiety appeared to be independent factors discriminating ‘non-suppressors’ from ‘suppressors’, it is possible to speculate that there were two separate subgroups of patients with non-suppression: a predominantly anxious group, somewhat younger in age, with an earlier age of onset; and a predominantly retarded group, with later age of onset. It is possible that these differences between the two groups merely reflect a tendency for younger depressed patients to present with anxiety, while older patients present with retardation. However, the fact that later age of onset of first episode rather than older present age was associated with retardation is inconsistent with this, and suggests that there may be two subgroups of patients with non-suppression or, more likely, two processes accounting for non-suppression within any group of patients.

The two processes might represent quite different patterns of neurotransmitter dysfunction producing disinhibition of the HPA axis and non-suppression. The possibility that depressed patients who are ‘non-suppressors’ have different underlying neurotransmitter abnormalities has important implications for future research into aetiology and treatment. The failure of Greider et al. (1981) to replicate the reports of Brown et al. (1980) that ‘non-suppressors’ responded better to antidepressants with predominantly noradrenergic-uptake-inhibiting activity may, in part, be explained by the heterogeneity of the ‘non-suppressor’ group of depressed patients.

We would like to acknowledge the assistance of Dr. T. Craig, Ms. K. Scott and Ms. M. C. for their help. This study was conducted at the Health Centre, R. J. Dolan.

REFERENCE


The result of the depressive symptom across the c

These results: two differentially exclusive groups of depressed patients.

We would like to acknowledge the assistance of Dr. T. Craig, Ms. J. K. Scott and Ms. M. C. for their help. This study was conducted at the Health Centre, R. J. Dolan.
The results of this study call into question the use of the DST to identify any particular depressive syndrome as the abnormality occurred across all the currently used diagnostic categories. These results suggest that there might be at least two different mechanisms, not necessarily mutually exclusive, accounting for non-suppression in depressed patients.

We would like to thank Dr. A. Mann, Dr. J. M. Kennedy, Professor G. W. Brown, Dr. T. Harris, Dr. T. Craig, Ms. K. Wood, Dr. A. Higgitt, Ms. M. Hakda, Ms. K. Scott and Ms. L. J. Dunlop Humphrey for their help, and the staff of Nicol Ward and the Caversham Health Centre, Kentish Town, for their cooperation. This study was carried out while S. F. Calloway and R. J. Dolan were Wellcome Research Fellows.

REFERENCES


---

**SYNOPS**
thyroid-thyroid patients. response of derer and any Pateri enviroment that the depresses of thyro be due to would n

---

**INTRO**
There is a thalamic following patients mono (T: hormone *et al.* 1977, to have i comparis illnesses: 1978, as depressed to TRH across dif There is, about the blunted n patients responses augmente...